Cancer Research Technology Ltd.
Division of Cancer Research UK
Latest From Cancer Research Technology Ltd.
Third quarter biopharma start-up financing activity decreased from the record-breaking Q2. A review of biopharma start-up dealmaking and financing activity from July through September 2018, based on data from Strategic Transactions.
Companies filling positions include Sanofi, with a new head of business transformation, and MSD Research Laboratories, with a leader for its new London early discovery facility. There is new leadership for Pandion Therapeutics, and further C-suite appointments at Orchard Therapeutics, Redx Pharma, Glythera and Inotrem.
While Mustang was acquiring CAR-T intellectual property from Harvard and Juno licensed gamma-secretase inhibitor IP from OncoTracker and Fred Hutchinson for use with its CAR-Ts, Ocugen and Tamid licensed gene therapy research for ophthalmic uses.
The clinical-stage biopharma's latest financing of $58m will be used to progress its immunotherapy pipeline and proprietary platform, bringing its funding to date to just over $230m.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.